News and Trends 5 Aug 2022
Neurocrine to conduct placebo-controlled study to investigate potential new treatment for schizophrenia
A phase 2 clinical trial for the treatment of schizophrenia has been accepted by the US Food and Drug Administration (FDA) and a study can now go ahead. Neurocrine Biosciences received the news and informed its partner Sosei Group Corporation. The approval of the study of NBI-1117568 has triggered a $30 million payment to Sosei. […]
